LOPA: The Comparision of Laparoscopic and Open Pancreaticoduodenectomy for Pancreatic Cancer

Sponsor
Peking Union Medical College Hospital (Other)
Overall Status
Unknown status
CT.gov ID
NCT03747588
Collaborator
(none)
100
2
25

Study Details

Study Description

Brief Summary

Minimally invasive pancreaticoduodenectomy remains one of the most challenging abdominal procedures. Safety and feasibility remain controversial when comparing laparoscopic with open pancreaticoduodenectomy,especially for malignant tumors.The aim of this study was to compare laparoscopic and open pancreatoduodenectomy for short-term outcomes in a randomized trial.

Condition or Disease Intervention/Treatment Phase
  • Other: Laparoscopic pancreaticoduodenectomy
  • Other: Open pancreaticoduodenectomy
N/A

Detailed Description

This study is to compare the efficiency and safety between laparoscopic and open pancreaticoduodenectomy for pancreatic cancer. We design a prospective randomized study. Patients with malignant pancreatic tumor who underwent pancreatoduodenectomy are recruited to the study. After obtaining informed consent, eligible patients are randomly allocated to laparoscopic or open group before the operation day . The outcomes evaluated were hospital stay, and blood loss, radicality of surgery, duration of operation and complication rate.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
100 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
The Effect and Safety of Comparision Between Laparoscopic and Open Pancreaticoduodenectomy for Pancreatic Cancer : A Randomized Prospective Trial
Anticipated Study Start Date :
Dec 1, 2018
Anticipated Primary Completion Date :
Nov 1, 2020
Anticipated Study Completion Date :
Dec 30, 2020

Arms and Interventions

Arm Intervention/Treatment
Experimental: Laparoscopic Pancreaticoduodenectomy

LPD

Other: Laparoscopic pancreaticoduodenectomy
Laparoscopic resection of pancreatic tumor

Placebo Comparator: Open Pancreaticoduodenectomy

OPD

Other: Open pancreaticoduodenectomy
open resection of pancreatic tumor

Outcome Measures

Primary Outcome Measures

  1. Overall complications [Up to postoperative 30 days]

    The proportion of all complications after operation accounted for the total number of patients

  2. Pancreatic fistula [Up to postoperative 30 days]

    The international study group (ISGPF) definition: A drain output of any measurable volume of fluid on or after postoperative day 3 with an amylase content greater than 3 times the serum amylase activity. Three different grades of postoperative fistula (grades A, B, C) are defined according to the clinical impact on the patient's hospital course.

  3. Intra-abdominal bleeding [Up to postoperative 30 days]

    The International Study Group of Pancreatic Surgery (ISGPS) definition: Blood loss through abdominal drains or nasogastric tube;hematemesis or melena; clinical deterioration of the patient; unexplained hypotension or tachycardia; or laboratory findings such as a decreasing hemoglobin concentration.

  4. Intra-abdominal infection [Up to postoperative 30 days]

    Positive cultures of collection of fluid or blood,or persistent fever necessitating treatment with antibiotics and positive detection in image test.

Secondary Outcome Measures

  1. Length of hospital stay (day) [Up to postoperative 2 weeks]

    Participants will be followed for the duration of hospital stay, an expected average of 2 weeks

Other Outcome Measures

  1. progression-free survival [Up to postoperative 5 years]

    The period between the beginning of treatment and the observation of disease progression or the occurrence of death for any reason.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 75 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Age: >18yr, <75yr

  • Patients with pancreatic cancer or non-pancreatic cancers (biliary duct cancer or ampullary cancer) who underwent pancreatoduodenectomy

  • Preoperative imaging assessment is resectable or borderline resectable

Exclusion Criteria:
  • Benign tumors of the head of pancreas

  • Enhanced CT diagnosis revealed that the excess of SMV was more than 180 degrees, or distant metastasis.

  • conversion to laparotomy because of intraoperative difficulty

Contacts and Locations

Locations

No locations specified.

Sponsors and Collaborators

  • Peking Union Medical College Hospital

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Peking Union Medical College Hospital
ClinicalTrials.gov Identifier:
NCT03747588
Other Study ID Numbers:
  • Pumch06342
First Posted:
Nov 20, 2018
Last Update Posted:
Nov 23, 2018
Last Verified:
Nov 1, 2018
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Peking Union Medical College Hospital
Additional relevant MeSH terms:

Study Results

No Results Posted as of Nov 23, 2018